A

AbbVie

Global biopharmaceutical company developing medicines

Finance Manager - Skincare

Full-TimePosted on 10/21/2026
$109.5k - $208.5k/yr+ Long-term incentive program
Senior, Expert
Bachelor's
Irvine, CA, USA
Hybrid3 days in office and 2 days remote; additional office days as needed.
Finance & BankingCorporate Finance & FP&A

About the job

Requirements
  • At least 8 years of combined experience in Commercial Finance, P&L management, revenue forecasting, financial planning and analysis, cost accounting, auditing, and financial reporting.
  • A bachelor's degree in finance or accounting.
  • Leadership skills and the capability to direct efforts to achieve answers and results.
  • Strong financial, analytical, problem-solving, communication, and presentation skills.
  • Ability to think creatively and strategically, identify key issues, opportunities, and value drivers, and translate strategic insights into appropriate forecasts to drive business decisions.
  • Ability to understand market research and assess and quantify the financial impacts of marketing initiatives, promotional activities, and competitive events.
  • Ability to triangulate a wide variety of data sets and analytics to inform forecasting and solve business problems through proactive issue identification and the collection, analysis, and interpretation of related data.
  • Ability to lead teams, manage multiple tasks concurrently in a dynamic environment, and ensure high-quality, timely work product.
  • Ability to gain alignment and partner effectively with cross-functional stakeholders across varying levels of management, and to influence without direct authority.
  • Experience working in a dynamic business environment under tight timelines and quick turnarounds to achieve results and deliverables.
  • Demonstrated ability to communicate actions, decisions, and concerns in a timely and effective manner.
  • Understanding of AbbVie's financial policies (CFMs) and Generally Accepted Accounting Principles.
  • Solid understanding of systems and automation tools such as SAP, BPC, Power BI, and Excel.
Responsibilities
  • Lead the US Skincare Finance team, including managing direct reports, coaching, and people development.
  • Lead P&L management and the demand and revenue forecasting process for US Skincare.
  • Own and continuously improve driver-based demand and revenue forecasting models for US Skincare, ensuring timely, accurate, and decision-relevant outputs across all planning cycles.
  • Drive US Skincare projects to achieve commercial objectives and financial controls.
  • Translate complex financial and commercial insights into clear executive narratives and recommendations while ensuring compliance with applicable financial, legal, and corporate requirements.
  • Identify key insights from data analysis and highlight trends, opportunities, and risks.
  • Develop and drive solutions and strategies to enhance operational performance and address business issues.
  • Lead execution of LBEs, Plan, LRP, ADS, and S&OP forecasts by aligning with Commercial, Finance, Operations, and other cross-functional stakeholders.
  • Manage P&L, including standard margin, OMC, OCOGS, and SG&A.
  • Oversee SG&A, headcount, and CAPEX for US Skincare.
  • Lead the monthly demand review; analyze forecasting trends, forecast accuracy, and forecast proposals with Commercial, Global Operations, and other stakeholders.
  • Prepare and submit Plan, LBEs, LRP, ADS, and S&OP materials and supporting documentation accurately, completely, and on time for review meetings.
  • Develop channel-level forecasts, monitor performance drivers, historical trends, and market dynamics, and use market data, promotional activities, in-field insights, analytics, channel evolution, and market events to identify patterns, compare market trends, and improve accuracy and predictability of results and key metrics.
  • Apply technical expertise to refine forecasting models and support strategic business decisions.
  • Develop forecasts by understanding performance drivers across channels, customers, and tiers, and analyze volume and SKU mix trends.
  • Collaborate with stakeholders to validate and integrate actuals into forecasting models, ensuring integrity and accuracy.
  • Develop revenue targets for the sales force in coordination with the Incentive Compensation team.
  • Develop and maintain financial forecasts for upcoming assets to support launch planning and execution.
  • Develop and maintain financial scenario models based on business insights and performance drivers for revenue and investment analysis, including business cases, promotional offers, P&L forecasts, profitability, ROI analysis, and RCEs.
  • Lead investment analysis, including cross-brand portfolio financial management.
  • Compile comprehensive reports and presentations that distill market dynamics and financial outcomes, and present sales results and future forecasts to Commercial with strategic context.
  • Prepare financial reports such as sales roll-forward, key opportunities and risks, and PPD schedules versus benchmarks, with clear narratives and supporting documentation.
  • Prepare ad hoc financial analysis to support informed decision-making.
  • Engage with cross-functional teams to address business challenges and provide strategic financial insights and solutions.
  • Facilitate effective communication with management on forecast processes, issues, and strategic rationale.
  • Partner with Global Operations, including Brand Operations, Demand Planning, Supply Planning, and S&OP, to align supply and demand forecasts and optimize inventory, E&O, and cash flow.
  • Coordinate with GCD and MABI to stay informed about competitor activities and market developments.
  • Serve as the US Skincare liaison with Gross-to-Net and Loyalty Programs, Field Force Operations, Incentive Compensation, Operations, FSS, and Customer Service.
  • Drive continuous process improvement and refine forecasting processes to enhance data-analysis efficiency and communication.
  • Collaborate on ad hoc analyses of business performance issues and provide clear resolutions.
  • Prepare reports to support earnings calls and external communications.
  • Support ad hoc requests, lead projects, and participate in corporate initiatives.
Desired Qualifications
  • Forecasting experience.
  • Project management experience.
  • Prior pharmaceutical or consumer industry experience.
  • AI automation capabilities.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 23rd, 2026
ETFs net sell $42.1M of AbbVie as XLV leads $32.0M exit

Exchange-traded funds (ETFs) were net sellers of AbbVie shares for a second straight session, selling a net $42.1 million on October 21. Sellers moved larger sums even though more funds bought than sold: 24 ETFs added shares and 23 cut them. The Health Care Select Sector SPDR Fund led the selling with $32.0 million, followed by iShares Core S&P 500 ETF at $9.3 million and SPDR S&P 500 ETF Trust at $2.0 million. On October 20, ETFs sold a net $6.7 million, after three days of net buying. AbbVie has a market cap of $504.0 billion. Trailing 12-month revenue was $64.39 billion, up 10.3% over the past year.

Yahoo Finance
Oct 22nd, 2026
Abbott stock: $247,767 in shares yields $500 a month in dividends ahead of Q3 earnings

Abbott Laboratories will report third-quarter earnings before the market opens on Wednesday, October 21. Analysts expect earnings of $1.41 per share, up from $1.30 a year earlier, and revenue of $12.99 billion, against $11.37 billion last year. On October 16, TD Cowen analyst Joshua Jennings reiterated a Buy rating and a $135 price target. Abbott pays a quarterly dividend of 63 cents per share ($2.52 a year), a yield of 2.42%. To earn $500 a month ($6,000 a year) from dividends alone, an investor would need about 2,381 shares, or roughly $247,767.

Yahoo Finance
Oct 21st, 2026
Retirees swap Social Security for 5 dividend stocks yielding up to 6.64%

Retirees looking for income beyond Social Security are turning to dividend stocks. The 2027 cost-of-living adjustment is tracking toward 3.3%, and five companies from different industries were screened for dividend safety first, then yield. Verizon yields 6.64% and Altria 6.17%. Verizon's free cash flow guidance of $21.94 billion to $22.14 billion covers its roughly $11.76 billion annual dividend. Altria's payout is about 79% of the low end of its 2026 earnings guidance. Realty Income pays monthly at a 5.99% yield and has raised its dividend 115 consecutive quarters. Enbridge yields 5.95%. AbbVie yields 2.48%, but its quarterly dividend has grown from $0.40 in 2013 to $1.73 in 2026. Risks include satellite competition for Verizon, falling cigarette volumes for Altria, and currency swings for Enbridge.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.

Yahoo Finance
Oct 19th, 2026
Buffett warns of a "gambling mood" in markets; Vertex, Eli Lilly and AbbVie built to weather a drop

Warren Buffett, now Berkshire Hathaway's chairman emeritus, gave his bluntest warning yet at the May shareholder meeting. "We've never had people in a more gambling mood than now," he told CNBC, pointing to individuals rushing into short-term options and betting on markets. He said this behaviour is risky for those taking part and may threaten the market, possibly leading to a drop. The article suggests drugmakers as defensive picks, since patients need treatments in any economy. Vertex Pharmaceuticals leads in cystic fibrosis treatment. Eli Lilly's tirzepatide drugs, Mounjaro and Zepbound, earned more than $14 billion of its $23 billion quarterly revenue. AbbVie's Rinvoq and Skyrizi each grew 24%, and it has raised its dividend for more than 50 consecutive years.